Neumarker was established in 2022 in Silicon Valley by two serial entrepreneurs driven by a passion to improve healthcare for patients battling CNS diseases. Founded by individuals who understand firsthand the challenges of treating CNS diseases, such as ADHD and Alzheimer’s Disease, the company is dedicated to innovating and improving health care for CNS patients.
Our mission is to advance the understanding and treatment of central nervous system (CNS) diseases through innovative biomarker technology. We aim to bridge the gap between neuroscience and healthcare using machine learning to improve diagnostic precision and treatment outcomes. Neumarker is committed to the future of personalized medicine in neuropsychiatry and our team aspires to enhance patient care.
Built on a foundation of scientific excellence and integrity, we strive to lead in biomarker discovery and implementation. Our goal is to empower clinicians, support pharmaceutical advancements, and provide hope to patients with CNS disorders. Through collaborative research and rigorous inquiry, Neumarker is contributing to healthcare innovation and therapeutic development.
Our vision extends beyond current scientific boundaries, as we work to unlock the potential of personalized medicine. By harnessing neural functional connectivity and advanced analytics, including machine learning, we're challenging existing paradigms in CNS disease treatment and working towards a future where each patient receives tailored care.
Dr. Wang has 20 years of startup experience spanning multiple industries. His current and prior roles include Co-Founder and Chairman of the Board at Telesair, Inc., Co-Founder of WMTherapeutics, Venture Partner at Ferry Venture Capital, President at Movella, and Board Director at Mesa Biotech, Inc..
Dr. Wang holds a B.S. from Peking Univ
Dr. Wang has 20 years of startup experience spanning multiple industries. His current and prior roles include Co-Founder and Chairman of the Board at Telesair, Inc., Co-Founder of WMTherapeutics, Venture Partner at Ferry Venture Capital, President at Movella, and Board Director at Mesa Biotech, Inc..
Dr. Wang holds a B.S. from Peking University, a Ph.D. in Biophysics from the University of California, Berkeley, and an MBA in finance from the Wharton School of the University of Pennsylvania.
Dr. Li has 30 years of experience in the electrical engineering and computer industry. His expertise spans a wide spectrum of technical domains, including data analytics, machine learning in medical applications, network and data security, and data management infrastructures. He was a tenured faculty of the computer engineering department
Dr. Li has 30 years of experience in the electrical engineering and computer industry. His expertise spans a wide spectrum of technical domains, including data analytics, machine learning in medical applications, network and data security, and data management infrastructures. He was a tenured faculty of the computer engineering department at Santa Clara University for 20 years. He co-founded 3 startups and has pioneered technologies that are being used by nearly a billion people worldwide.
Dr. Li received a B.A. from Xian Jiaotong University, and an M.S. and Ph.D. from Florida International University.
Dr. Detke, a Board-certified Psychiatrist, brings 25 years of CNS drug development experience across various diseases and development phases. As a C-level executive, he oversaw clinical development at Cortexyme, Lighthouse, Embera and CoMentis. He also led signal detection improvement for CNS clinical trials at MedAvante. At Eli Lilly, he
Dr. Detke, a Board-certified Psychiatrist, brings 25 years of CNS drug development experience across various diseases and development phases. As a C-level executive, he oversaw clinical development at Cortexyme, Lighthouse, Embera and CoMentis. He also led signal detection improvement for CNS clinical trials at MedAvante. At Eli Lilly, he managed all early-phase CNS assets and spearheaded Phase 3 development for Cymbalta and Phase 4 for Prozac.
Dr. Detke received his B.A. and M.S. from the Yale University, M.D. and Ph.D. from the University of Pennsylvania, and completed his Psychiatry Residency training at Harvard/MGH/McLean.
Dr. Breier, formerly Chief Medical Officer at Eli Lilly, is now Professor of Psychiatry at Indiana University School of Medicine, leading the Psychotic Disorders Program. He has held various leadership roles in academia and industry, authored over 250 scientific articles, and earned a B.A. from the University of Toledo and an M.D. from the University of Cincinnati.
Dr. Potter, a leading expert in psychopharmacological sciences, spent over 25 years at the National Institutes of Health focusing on translational neuroscience. With leadership roles at Lilly Research Labs and Merck, he advanced methods for evaluating CNS effects of compounds, championing disciplined hypothesis testing in CNS drug development. He holds multiple degrees from Indiana University.
Dr. Wolkowitz, Psychiatry Professor at UCSF, focuses on affective and anxiety disorders, emphasizing stress-related mental illnesses like Major Depression and PTSD. He aims to identify stress effects on psychiatric and physical health, seeking novel therapeutic targets. He has published extensively and received many awards, holding an M.D. from the University of Maryland.
We're proud of our innovation, dedication, passion, and the team we have assembled since our inception in 2022. Here are some of what makes us unique:
Copyright © 2024 Neumarker Inc. - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.